NASDAQ:NKTR - Nektar Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.00
  • Forecasted Upside: 36.42 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$16.86
▼ -0.14 (-0.82%)

This chart shows the closing price for NKTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nektar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTR

Analyst Price Target is $23.00
▲ +36.42% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $23.00, with a high forecast of $26.00 and a low forecast of $18.00. The average price target represents a 36.42% upside from the last price of $16.86.

This chart shows the closing price for NKTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Nektar Therapeutics. This rating has held steady since March 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 1 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 1 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 1 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 1 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2021SVB LeerinkLower Price TargetMarket Perform$21.00 ➝ $20.00Low
5/7/2021MizuhoReiterated RatingBuyHigh
4/6/2021SVB LeerinkBoost Price TargetMarket Perform$20.00 ➝ $21.00Low
3/1/2021BenchmarkReiterated RatingBuy ➝ Hold$26.00Low
2/22/2021BenchmarkDowngradeBuy ➝ Hold$26.00High
1/5/2021Stifel NicolausInitiated CoverageHold$18.00N/A
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$17.00 ➝ $20.00Low
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral$26.00High
8/14/2020SVB LeerinkLower Price TargetMarket Perform$18.00 ➝ $17.00Medium
8/7/2020OppenheimerReiterated RatingHold$25.00High
6/10/2020CfraDowngradeHold ➝ SellLow
5/26/2020MizuhoInitiated CoverageBuy$35.00Low
5/18/2020OppenheimerBoost Price TargetMarket Perform$24.00 ➝ $25.00Medium
5/12/2020HC WainwrightLower Price TargetNeutral$32.00 ➝ $26.00High
5/8/2020SVB LeerinkBoost Price TargetMarket Perform$17.00 ➝ $18.00High
4/22/2020BenchmarkInitiated CoverageBuy$26.00Medium
4/2/2020MizuhoReiterated RatingBuy$35.00High
3/30/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral$18.00 ➝ $20.00Low
3/9/2020JPMorgan Chase & Co.Lower Price TargetNeutral$28.00 ➝ $27.00High
3/4/2020BarclaysInitiated CoverageOverweight$30.00High
2/28/2020Piper SandlerReiterated RatingBuy$35.00High
2/28/2020BTIG ResearchLower Price TargetBuy$101.00 ➝ $80.00High
2/28/2020William BlairReiterated RatingOutperformHigh
2/28/2020CowenReiterated RatingBuy$27.00Low
2/12/2020CowenReiterated RatingBuy$30.00Medium
2/3/2020MizuhoReiterated RatingNeutral ➝ Buy$21.00 ➝ $35.00High
1/10/2020MizuhoInitiated CoverageHold$21.00High
1/10/2020HC WainwrightReiterated RatingHold$32.00High
11/12/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.00Medium
11/11/2019HC WainwrightBoost Price TargetNeutral$24.00 ➝ $32.00High
11/7/2019Piper Jaffray CompaniesLower Price TargetOverweight$50.00 ➝ $35.00High
11/7/2019CowenReiterated RatingBuyHigh
11/7/2019MizuhoReiterated RatingHold$21.00High
10/24/2019OppenheimerInitiated CoverageMarket Perform$18.00Medium
10/8/2019The Goldman Sachs GroupDowngradeBuy ➝ Sell$54.00 ➝ $16.00High
9/30/2019HC WainwrightSet Price TargetHold$24.00High
9/26/2019CowenSet Price TargetBuy$43.00Medium
9/26/2019William BlairReiterated RatingBuyMedium
9/26/2019Piper Jaffray CompaniesSet Price TargetBuy$50.00Medium
8/13/2019HC WainwrightReiterated RatingHoldMedium
8/11/2019Evercore ISIReiterated RatingHold$37.00High
8/9/2019William BlairReiterated RatingBuyLow
8/9/2019CfraSet Price TargetHold$35.00Low
8/9/2019BMO Capital MarketsLower Price TargetOutperform$75.00 ➝ $41.00High
8/9/2019MizuhoDowngradeBuy ➝ Neutral$79.00 ➝ $21.00High
8/9/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$62.00 ➝ $33.00High
8/9/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$59.00 ➝ $23.00High
8/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $100.00High
7/26/2019MizuhoLower Price TargetBuy$81.00 ➝ $79.00High
6/14/2019William BlairReiterated RatingBuyMedium
6/13/2019CowenSet Price TargetBuy$82.00Medium
6/4/2019William BlairReiterated RatingBuyMedium
6/2/2019CowenSet Price TargetBuy$82.00High
5/24/2019MizuhoReiterated RatingBuy$81.00Low
3/15/2019SVB LeerinkInitiated CoverageMkt Perform$38.00Medium
3/4/2019HC WainwrightReiterated RatingHold$47.00Low
3/1/2019Piper Jaffray CompaniesSet Price TargetBuy$100.00Low
3/1/2019MizuhoReiterated RatingBuy$81.00High
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$75.00Medium
2/19/2019MizuhoReiterated RatingBuyLow
2/19/2019HC WainwrightReiterated RatingHold$47.00Low
1/23/2019MizuhoReiterated RatingBuy$81.00 ➝ $81.00Low
12/13/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Buy$81.00 ➝ $62.00High
11/13/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$94.00 ➝ $86.00High
11/12/2018HC WainwrightSet Price TargetHold$47.00High
11/8/2018CowenReiterated RatingBuy$86.00High
11/8/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$103.00 ➝ $73.00High
11/5/2018HC WainwrightReiterated RatingHold$47.00Medium
10/22/2018HC WainwrightSet Price TargetHold$54.00High
8/10/2018HC WainwrightSet Price TargetHold$54.00Medium
8/9/2018William BlairReiterated RatingOutperformHigh
8/9/2018CowenReiterated RatingBuy$86.00High
8/9/2018MizuhoReiterated RatingBuy$103.00High
8/8/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
7/31/2018HC WainwrightReiterated RatingHold$54.00Low
7/25/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
6/11/2018HC WainwrightDowngradeBuy ➝ Neutral$54.00Low
6/4/2018William BlairReiterated RatingBuyHigh
6/4/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$90.00 ➝ $78.00High
6/4/2018HC WainwrightLower Price TargetBuy$97.00High
5/20/2018HC WainwrightSet Price TargetBuy$125.00Low
5/14/2018HC WainwrightSet Price TargetBuy$125.00Medium
5/11/2018Canaccord GenuitySet Price TargetBuy$94.00Low
5/11/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00High
4/30/2018HC WainwrightSet Price TargetBuy$125.00Low
4/26/2018Piper Jaffray CompaniesSet Price TargetBuy$125.00Low
4/20/2018Seaport Global SecuritiesInitiated CoverageBuy$120.00Low
4/17/2018HC WainwrightSet Price TargetBuy$125.00Low
4/17/2018MizuhoReiterated RatingBuy$103.00Low
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$125.00Medium
4/9/2018HC WainwrightSet Price TargetBuy$125.00High
4/6/2018MizuhoBoost Price TargetBuy ➝ Buy$89.00 ➝ $103.00Medium
4/2/2018HC WainwrightReiterated RatingBuy ➝ Buy$125.00High
3/29/2018MizuhoSet Price TargetBuy$89.00Low
3/2/2018CowenReiterated RatingBuy$101.00Low
3/2/2018Jefferies Financial GroupBoost Price TargetBuy$103.00High
3/2/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$94.00High
2/14/2018MizuhoReiterated RatingBuy$89.00Medium
1/22/2018MizuhoBoost Price TargetBuy ➝ Buy$45.00 ➝ $89.00High
1/16/2018Jefferies Financial GroupBoost Price TargetBuy$2.12 ➝ $88.00High
1/10/2018Canaccord GenuityReiterated RatingBuy$50.00 ➝ $80.00Low
11/15/2017Canaccord Genuity GroupBoost Price TargetBuy$35.00 ➝ $50.00N/A
11/14/2017MizuhoBoost Price TargetBuy$30.00 ➝ $45.00N/A
11/13/2017Canaccord GenuityBoost Price TargetBuy$35.00 ➝ $50.00N/A
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/A
11/13/2017JPMorgan Chase & Co.Reiterated RatingPositive ➝ Buy$44.00N/A
11/9/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$35.00N/A
11/8/2017MizuhoReiterated RatingBuy ➝ Buy$30.00 ➝ $45.00N/A
11/8/2017Jefferies Financial GroupReiterated RatingBuy$35.00N/A
11/7/2017CowenInitiated CoverageOutperformN/A
9/26/2017MizuhoInitiated CoverageBuy$30.00High
8/18/2017Jefferies Financial GroupReiterated RatingBuy$23.00Low
8/17/2017Evercore ISIInitiated CoverageIn ➝ In-Line$20.00High
8/9/2017Roth CapitalSet Price TargetBuy$33.00High
8/7/2017HC WainwrightInitiated CoverageBuy ➝ Buy$31.00Low
7/21/2017Jefferies Financial GroupReiterated RatingBuy$23.00Medium
7/18/2017William BlairReiterated RatingOutperformLow
6/26/2017William BlairReiterated RatingOutperformLow
5/22/2017Roth CapitalSet Price TargetBuy$31.00Medium
5/11/2017Roth CapitalSet Price TargetBuy$31.00Low
5/10/2017Jefferies Financial GroupLower Price TargetBuy$25.00 ➝ $23.00Medium
5/10/2017AegisReiterated RatingBuy$27.00High
4/22/2017Jefferies Financial GroupSet Price TargetBuy$25.00Medium
4/11/2017Piper Jaffray CompaniesReiterated RatingOverweight$29.00Low
4/6/2017AegisBoost Price TargetBuy$24.00 ➝ $27.00Low
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 ➝ $27.00Medium
3/21/2017JPMorgan Chase & Co.Set Price TargetBuy$24.00Medium
3/21/2017Jefferies Financial GroupBoost Price TargetPositive$17.00 ➝ $25.00High
3/20/2017AegisBoost Price TargetBuy$21.00 ➝ $24.00High
3/20/2017Roth CapitalSet Price TargetBuy ➝ Buy$23.00 ➝ $31.00Medium
3/4/2017Roth CapitalSet Price TargetBuy$23.00N/A
3/3/2017Jefferies Financial GroupReiterated RatingBuy$15.00 ➝ $17.00N/A
3/2/2017AegisReiterated RatingBuy$21.00N/A
1/6/2017BTIG ResearchInitiated CoverageBuy$22.00N/A
12/28/2016AegisReiterated RatingBuy$21.00N/A
12/12/2016Piper Jaffray CompaniesSet Price TargetBuy$25.00N/A
11/24/2016AegisReiterated RatingBuyN/A
11/8/2016AegisInitiated CoverageBuy$21.00N/A
11/7/2016Jefferies Financial GroupBoost Price TargetBuy$14.00 ➝ $15.00N/A
10/1/2016Piper Jaffray CompaniesSet Price TargetBuy$25.00N/A
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/A
9/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
8/5/2016Piper Jaffray CompaniesReiterated RatingOverweight$17.00 ➝ $21.00N/A
8/5/2016Brean CapitalReiterated RatingBuy$18.00N/A
(Data available from 6/21/2016 forward)
Nektar Therapeutics logo
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Read More

Today's Range

Now: $16.86
Low: $16.66
High: $17.05

50 Day Range

MA: $18.51
Low: $16.52
High: $20.39

52 Week Range

Now: $16.86
Low: $15.40
High: $26.75

Volume

36,007 shs

Average Volume

1,117,421 shs

Market Capitalization

$3.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?

The following sell-side analysts have issued stock ratings on Nektar Therapeutics in the last year: Benchmark Co., JPMorgan Chase & Co., Mizuho, Oppenheimer Holdings Inc., Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for NKTR.

What is the current price target for Nektar Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Nektar Therapeutics in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 35.3%. JPMorgan Chase & Co. has the highest price target set, predicting NKTR will reach $26.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $18.00 for Nektar Therapeutics in the next year.
View the latest price targets for NKTR.

What is the current consensus analyst rating for Nektar Therapeutics?

Nektar Therapeutics currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NKTR, but not buy more shares or sell existing shares.
View the latest ratings for NKTR.

What other companies compete with Nektar Therapeutics?

How do I contact Nektar Therapeutics' investor relations team?

Nektar Therapeutics' physical mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is 415-482-5300 and its investor relations email address is [email protected] The official website for Nektar Therapeutics is www.nektar.com.